Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 5/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.48 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.48 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.48 |
| ▸ | CPT2 | P23786 | 1/20 | 0.47 |
| ▸ | CPT1A | P50416 | 1/20 | 0.47 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774902 | 0.81 | CPT2 (0.45) | CPT2CPT1A | |
| SCHEMBL5776395 | 0.81 | TMEM97 (0.45) | CPT2CPT1A | |
| SCHEMBL5775332 | 0.81 | TMEM97 (0.45) | CPT2CPT1A | |
| SCHEMBL28864977 | 0.77 | ABHD6 (0.49) | CPT2CPT1A | |
| SCHEMBL5773186 | 0.76 | HRH3 (0.47) | CPT2CPT1A | |
| SCHEMBL5778766 | 0.75 | KDM4E (0.48) | CPT2CPT1A | |
| SCHEMBL30470871 | 0.75 | CHRNB4 (0.57) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL22319858 | 0.75 | ABHD6 (0.55) | CPT2CPT1A | |
| SCHEMBL17607362 | 0.75 | ACACB (0.51) | CPT2CPT1A | |
| SCHEMBL20983789 | 0.74 | ABHD6 (0.69) | CPT2CPT1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | CHRNB4 432/4885CHRNA3 395/4885CHRNB2 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.